W E EVANS - JoVE Visualize

Showing results (191-200 of 274) with videos related to

Pageof 28

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984

The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexateW R Crom, C B Pratt, A A Green, et al.

The Journal of Pharmacology and Experimental Therapeutics|January 1, 1992

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemiaW E Evans, J H Rodman, M V Relling, et al.

Journal of Pharmaceutical Sciences|June 1, 1989

Hepatic drug clearance in children: studies with indocyanine green as a model substrateW E Evans, M V Relling, S de Graaf, et al.

Clinical Chemistry|December 1, 1980

Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatographyR G Buice, W E Evans, J Karas, et al.

Blood|March 1, 1997

Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemiaC L Chen, Q Liu, C H Pui, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1981

Cisplatin disposition in children and adolescents with cancerW R Crom, W E Evans, C B Pratt, et al.

Cancer|February 1, 1990

Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studiesC B Pratt, J E Champion, I D Fleming, et al.

The New England Journal of Medicine|February 20, 1986

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effectW E Evans, W R Crom, M Abromowitch, et al.

The Journal of Clinical Investigation|January 1, 1996

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexateE Masson, M V Relling, T W Synold, et al.

Cancer Research|September 15, 1988

Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemiaC H Pui, S S de Graaf, L W Dow, et al.

Pageof 28

Showing results (191-200 of 274) with videos related to

Sort By:

Pageof 28

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984

The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexateW R Crom, C B Pratt, A A Green, et al.

The Journal of Pharmacology and Experimental Therapeutics|January 1, 1992

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemiaW E Evans, J H Rodman, M V Relling, et al.

Journal of Pharmaceutical Sciences|June 1, 1989

Hepatic drug clearance in children: studies with indocyanine green as a model substrateW E Evans, M V Relling, S de Graaf, et al.

Clinical Chemistry|December 1, 1980

Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatographyR G Buice, W E Evans, J Karas, et al.

Blood|March 1, 1997

Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemiaC L Chen, Q Liu, C H Pui, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1981

Cisplatin disposition in children and adolescents with cancerW R Crom, W E Evans, C B Pratt, et al.

Cancer|February 1, 1990

Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studiesC B Pratt, J E Champion, I D Fleming, et al.

The New England Journal of Medicine|February 20, 1986

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effectW E Evans, W R Crom, M Abromowitch, et al.

The Journal of Clinical Investigation|January 1, 1996

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexateE Masson, M V Relling, T W Synold, et al.

Cancer Research|September 15, 1988

Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemiaC H Pui, S S de Graaf, L W Dow, et al.

Pageof 28